within Pharmacolibrary.Drugs.ATC.N;

model N05AE04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.0019666666666666665,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0072,
    k12             = 4.14,
    k21             = 4.14
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AE04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ziprasidone is an atypical antipsychotic medication primarily used for the treatment of schizophrenia and bipolar disorder in adults. It is approved for use and marketed under various brand names such as Geodon. Its mechanism of action involves antagonism at dopamine D2 and serotonin 5-HT2A receptors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Sutar, R, et al., &amp; Chaudhary, P (2021). Antipsychotics and hemodialysis: A systematic review. <i>Asian journal of psychiatry</i> 55 102484–None. DOI:<a href=\"https://doi.org/10.1016/j.ajp.2020.102484\">10.1016/j.ajp.2020.102484</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33341539/\">https://pubmed.ncbi.nlm.nih.gov/33341539</a></p></li><li><p>Muirhead, GJ, et al., &amp; Anziano, RJ (2000). Ziprasidone and the pharmacokinetics of a combined oral contraceptive. <i>British journal of clinical pharmacology</i> 49 Suppl 1(Suppl 1) 49S–56S. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.2000.00153.x\">10.1046/j.1365-2125.2000.00153.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10771454/\">https://pubmed.ncbi.nlm.nih.gov/10771454</a></p></li><li><p>Sacchetti, E, et al., &amp; Valsecchi, P (2011). Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review. <i>Expert review of clinical pharmacology</i> 4(2) 163–179. DOI:<a href=\"https://doi.org/10.1586/ecp.10.139\">10.1586/ecp.10.139</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22115400/\">https://pubmed.ncbi.nlm.nih.gov/22115400</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AE04;
